Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) this week reported its third quarter financial results for 2024, highlighting substantial progress in its PBFT02 gene therapy program for frontotemporal dementia …
Passage Bio Advances PBFT02 Gene Therapy Program Amidst Positive Q3 2024 Results Read More